Grape King Bio has released its full-year financial results for 2024, reporting a net profit of NT$1.448 billion. Despite a slight decline from NT$1.452 billion in 2022, the company maintained a strong earnings per share (EPS) of NT$9.78, nearly equating to its par value.
In Q4 2024, the company recorded a net profit of NT$446 million, marking a 7.4% increase from Q3, with a quarterly EPS of NT$3.02.
On February 26, Grape King Bio’s board of directors approved the H2 2024 dividend distribution, proposing a cash dividend of NT$4.2 per share. Based on the closing stock price of NT$149.5 on the same day, the cash dividend yield stands at 2.8%.
Grape King Bio reported January revenue of NT$696 million, reflecting a decline compared to the previous month and year-over-year performance. The company attributed this decline to the early arrival of the Lunar New Year holiday in January, which led to fewer working days.
However, when compared to January 2023, which also saw the Lunar New Year holiday, revenue remained in line with expectations. The company anticipates business momentum to recover in February, as the number of working days increases compared to the same period last year.
Given that 95% of Grape King Bio’s revenue originates from Chinese-speaking markets, the company emphasized that the Lunar New Year holiday significantly affects sales performance. As such, it recommends evaluating January and February combined for a more accurate assessment of its overall revenue trends.
With a solid financial position and strategic market focus, Grape King Bio continues to strengthen its operational resilience, positioning itself for sustained growth in the coming quarters.
Resource: 葡萄王去年全年EPS 9.78元、賺近一個股本 第4季獲利增7.4%
